TY - JOUR
T1 - Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries
AU - Moran, Andrew E.
AU - Farrell, Margaret
AU - Cazabon, Danielle
AU - Sahoo, Swagata Kumar
AU - Mugrditchian, Doris
AU - Pidugu, Anirudh
AU - Chivardi, Carlos
AU - Walbaum, Magdalena
AU - Alemayehu, Senait
AU - Isaranuwatchai, Wanrudee
AU - Ankurawaranon, Chaisiri
AU - Choudhury, Sohel R.
AU - Pickersgill, Sarah J.
AU - Watkins, David A.
AU - Husain, Muhammad Jami
AU - Rao, Krishna D.
AU - Matsushita, Kunihiro
AU - Marklund, Matti
AU - Hutchinson, Brian
AU - Nugent, Rachel
AU - Kostova, Deliana
AU - Garg, Renu
N1 - Funding Information:
Funding. AEM, MF, DC, SKS, DM, SA, WI, CA, SRC, SJP, DAW, MJH, KR, KM, MM, DK and RG all receive salary support for their parts of the research described in this review from Resolve to Save Lives, a global non-profit public health organization. Resolve to Save Lives is funded by grants from Bloomberg Philanthropies, the Bill and Melinda Gates Foundation and Gates Philanthropy Partners, which is funded with support from the Chan Zuckerberg Foundation. Support to BH and RN for the study Evaluating the cost-effectiveness of single pill antihypertensive medicine combination therapy in 24 low-and middle-income countries work is provided by Cooperative Agreement number 1NU2HGH000044-01-00 funded by the US Centers for Disease Control and Prevention. AP was supported by a Columbia University Global and Population Health inter-ship for the summer of 2021.
Publisher Copyright:
© 2022 Pan American Health Organization. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context. The World Health Organization (WHO) and the Pan American Health Organization (PAHO) established a standard, simplified Global HEARTS approach to hypertension control, including preferred antihypertensive medicines and blood pressure measurement devices. The objective of this study is to report on health economic studies of HEARTS hypertension control package cost (especially medication costs), cost-effectiveness, and budget impact and describe mathematical models designed to translate hypertension control program data into the optimal approach to hypertension care service delivery and financing, especially in lowand middle-income countries. Early results suggest that HEARTS hypertension control interventions are either cost-saving or cost-effective, that the HEARTS package is affordable at between US$ 18-44 per person treated per year, and that antihypertensive medicines could be priced low enough to reach a global standard of an average <US$ 5 per patient per year in the public sector. This health economic evidence will make a compelling case for government ownership and financial support for national scale hypertension control programs.
AB - Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context. The World Health Organization (WHO) and the Pan American Health Organization (PAHO) established a standard, simplified Global HEARTS approach to hypertension control, including preferred antihypertensive medicines and blood pressure measurement devices. The objective of this study is to report on health economic studies of HEARTS hypertension control package cost (especially medication costs), cost-effectiveness, and budget impact and describe mathematical models designed to translate hypertension control program data into the optimal approach to hypertension care service delivery and financing, especially in lowand middle-income countries. Early results suggest that HEARTS hypertension control interventions are either cost-saving or cost-effective, that the HEARTS package is affordable at between US$ 18-44 per person treated per year, and that antihypertensive medicines could be priced low enough to reach a global standard of an average <US$ 5 per patient per year in the public sector. This health economic evidence will make a compelling case for government ownership and financial support for national scale hypertension control programs.
KW - Health services accessibility
KW - cardiovascular diseases
KW - cost-benefit analysis
KW - hypertension
UR - http://www.scopus.com/inward/record.url?scp=85142048481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142048481&partnerID=8YFLogxK
U2 - 10.26633/RPSP.2022.140
DO - 10.26633/RPSP.2022.140
M3 - Article
C2 - 36071923
AN - SCOPUS:85142048481
SN - 1020-4989
VL - 46
JO - Revista Panamericana de Salud Publica/Pan American Journal of Public Health
JF - Revista Panamericana de Salud Publica/Pan American Journal of Public Health
M1 - e140
ER -